Middle East and Africa Omega 3 Ingredients for Pharmaceuticals Market - Industry Trends and Forecast to 2027
- DBMR1015
- Pages: 80
- July 2020
- Total Views:1139
- Region : Global
- Data Bridge Market Research
- Market Research Report
Details
Middle East and Africa omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 8.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Middle East and Africa Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA) and Alpha-Linolenic Acid (ALA)), Form (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer and Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (South Africa, Saudi Arabia, U.A.E., Kuwait and Rest of Middle East and Africa) Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of Middle East and Africa omega-3 ingredients for pharmaceuticals market are:
Growing demand of functional and supplement food
Rising burden of lifestyle diseases leads the demand of Omega-3 based products
Market Players:
The key market players for Middle East and Africa omega-3 ingredients for pharmaceuticals market are listed below:
AbbVie Inc.
BASF SE
Corbion NV
DSM
AstraZeneca
GlaxoSmithKline plc.
Strides Pharma Science Limited
Table Of Content
Scope
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 SOURCE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PATENT ANALYSIS
3.1.1 DBMR ANALYSIS
3.1.2 COUNTRY LEVEL INSIGHTS
3.1.3 COMPANY BASED ANALYSIS
3.2 PRICING ANALYSIS
4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: REGULATIONS
5 IMPACT OF COVID-19 PANDEMIC ON THE MIDDLE EAST AND AFRICA OMEGA 3 INGREDIENTS IN PHARMACEUTICALS MARKET
5.1 PRICE IMPACT
5.2 IMPACT ON DEMAND
5.3 IMPACT ON SUPPLY CHAIN
5.4 STRATEGIC DECISIONS FOR MANUFACTURERS
5.5 CONCLUSION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 CONSUMER AWARENESS REGARDING THE HEALTH BENEFITS OF OMEGA-3
6.1.2 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD
6.1.3 INCREASING PREFERENCES TOWARDS CERTIFIED FOOD INGREDIENTS
6.1.4 RISING BURDEN OF LIFESTYLE DISEASES LEADS THE DEMAND OF OMEGA-3 BASED PRODUCTS
6.2 RESTRAINTS
6.2.1 NEGATIVE CONSUMER PERCEPTION ABOUT THE SMELL AND TASTE OF OMEGA-3 INGREDIENTS
6.2.2 HIGH COSTS OF PRODUCTS
6.3 OPPORTUNITIES
6.3.1 GROWING RESEARCH FOR THE DEVELOPMENT OF ALTERNATIVE SOURCES TO OBTAIN OMEGA-3
6.3.2 RISE IN CONSUMER DEMAND FOR PLANT-BASED OMEGA-3 PRODUCTS
6.3.3 DEVELOPING TECHNOLOGIES TO INCREASE THE CONCENTRATION OF OMEGA-3 INGREDIENTS IN MEDICINES
6.4 CHALLENGES
6.4.1 SIDE EFFECTS AND ALLERGIES RELATED TO FISH-BASED PRODUCTS
6.4.2 SUSTAINABILITY ISSUES WITH OMEGA-3 RAW MATERIAL
7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE
7.1 OVERVIEW
7.2 MARINE
7.3 PLANT
8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DOCOSAHEXAENOIC ACID (DHA)
8.3 EICOSAPENTAENOIC ACID (EPA)
8.4 ALPHA-LINOLENIC ACID (ALA)
9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM
9.1 OVERVIEW
9.2 LIQUID
9.3 DRY
10 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS
10.1 OVERVIEW
10.2 CARDIOVASCULAR DISEASES
10.2.1 HYPERLIPIDEMIA
10.2.2 STROKES
10.2.3 HYPERTENSION
10.2.4 OTHERS
10.3 CANCER
10.3.1 PROSTATE CANCER
10.3.2 BREAST CANCER
10.3.3 COLORECTAL CANCER
10.3.4 OTHERS
10.4 NEUROLOGICAL DISORDERS
10.4.1 ALZHEIMER'S DISEASE
10.4.2 COGNITIVE DISORDERS
10.4.3 BIPOLAR DISORDERS
10.4.4 SCHIZOPHRENIA
10.4.5 OTHERS
10.5 AUTOIMMUNE DISEASES
10.5.1 RHEUMATOID ARTHRITIS
10.5.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
10.5.3 TYPE 1 DIABETES
10.5.4 OTHERS
10.6 BONE & JOINT DISORDERS
10.6.1 OSTEOPOROSIS
10.6.2 ARTHRITIS
10.6.3 OTHERS
10.7 SKIN HEALTH
10.7.1 ACNE
10.7.2 WRINKLES
10.7.3 SKIN AGING
10.7.4 OTHERS
10.8 OPHTHALMIC DISORDERS
10.8.1 DRY EYE SYNDROME
10.8.2 AGE-RELATED MACULAR DEGENERATION
10.8.3 OTHERS
10.9 OTHERS
11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE
11.1 OVERVIEW
11.2 ADULT
11.2.1 FEMALE
11.2.2 MALE
11.3 CHILDREN
12 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT
12.3 INDIRECT
13 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST & AFRICA
13.1.1 SOUTH AFRICA
13.1.2 UAE
13.1.3 SAUDI ARABIA
13.1.4 KUWAIT
13.1.5 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 CRODA INTERNATIONAL PLC
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 CORBION
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 DSM
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 KD PHARMA GROUP
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 STRIDES PHARMA SCIENCE LIMITED
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BASF SE
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 PHARMA MARINE AS
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ABBVIE INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 AMARIN CORPORATION
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.10 ANI PHARMACEUTICALS, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 ASTRAZENECA
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 AVESTIA PHARMA
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 CAMBER PHARMACEUTICALS, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 EPAX (A SUBSIDIARY OF PELAGIA AS)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG)
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENT
16.16 GLAXOSMITHKLINE PLC
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 KINOMEGA BIOPHARM INC
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 NOVASEP
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
16.19 SOLUTEX
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List Of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 10 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 11 MARINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN 2020 & 2027
FIGURE 12 PATENT REGISTERED FOR OMEGA-3, BY COUNTRY
FIGURE 13 PATENT REGISTERED BY YEAR (2000-2020)
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET
FIGURE 15 PREVALENCE OF LIFESTYLE CHRONIC DISEASES (IN MILLIONS)
FIGURE 16 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019
FIGURE 17 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019-2027 (USD THOUSANDS)
FIGURE 18 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, CAGR (2020-2027)
FIGURE 19 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019
FIGURE 21 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019-2027 (USD THOUSANDS)
FIGURE 22 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 23 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019
FIGURE 25 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019-2027 (USD THOUSANDS)
FIGURE 26 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, CAGR (2020-2027)
FIGURE 27 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, 2019
FIGURE 29 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC ARES, 2019-2027 (USD THOUSANDS)
FIGURE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)
FIGURE 31 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019
FIGURE 33 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019-2027 (USD THOUSANDS)
FIGURE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, CAGR (2020-2027)
FIGURE 35 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 37 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSANDS)
FIGURE 38 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 39 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019)
FIGURE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019)
FIGURE 42 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027)
FIGURE 43 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027)
FIGURE 44 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027)
FIGURE 45 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%)
List Of Table
LIST OF TABLES
TABLE 1 THE PRICE RANGE OF OMEGA-3 INGREDIENTS
TABLE 2 COST COMPARISION OF MARINE SOURCES OF OMEGA-3 INGREDIENTS
TABLE 3 COST OF PRODUCTS
TABLE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 5 MIDDLE EAST AND AFRICA MARINE IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 6 MIDDLE EAST AND AFRICA PLANT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 8 MIDDLE EAST AND AFRICA DOCOSAHEXAENOIC ACID (DHA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 9 MIDDLE EAST AND AFRICA EICOSAPENTAENOIC ACID (EPA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 10 MIDDLE EAST AND AFRICA ALPHA-LINOLENIC ACID (ALA)IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM , 2017-2026 (USD THOUSANDS)
TABLE 12 MIDDLE EAST AND AFRICA LIQUID IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 13 MIDDLE EAST AND AFRICA DRY IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 15 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 16 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 17 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 18 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 19 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 20 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 21 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 22 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 23 MIDDLE EAST AND AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 24 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 25 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 26 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 27 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 28 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 31 GLOBA ADULT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 32 MIDDLE EAST AND AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 33 GLOBA CHILDREN IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 35 MIDDLE EAST AND AFRICA DIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 36 MIDDLE EAST AND AFRICA INDIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 37 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY COUNTRY, 2018-2027 (USD THOUSANDS)
TABLE 38 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 39 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 42 MIDDLE EAST & AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 43 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 44 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 45 MIDDLE EAST & AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 46 MIDDLE EAST & AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 47 MIDDLE EAST & AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 48 MIDDLE EAST & AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 49 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 50 MIDDLE EAST & AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 51 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 52 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 53 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 54 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 55 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 56 SOUTH AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 57 SOUTH AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 58 SOUTH AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 59 SOUTH AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 60 SOUTH AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 61 SOUTH AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 62 SOUTH AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 63 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 64 SOUTH AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 65 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 66 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 67 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 68 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 69 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 70 UAE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 71 UAE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 72 UAE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 73 UAE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 74 UAE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 75 UAE BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 76 UAE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 77 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 78 UAE ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 79 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 80 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 81 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 82 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 83 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 84 SAUDI ARABIA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 85 SAUDI ARABIA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 86 SAUDI ARABIA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 87 SAUDI ARABIA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 88 SAUDI ARABIA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 89 SAUDI ARABIA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 90 SAUDI ARABIA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 91 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 92 SAUDI ARABIA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 93 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 94 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 95 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 96 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 97 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 98 KUWAIT OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 99 KUWAIT NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 100 KUWAIT CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 101 KUWAIT AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 102 KUWAIT CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 103 KUWAIT BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 104 KUWAIT SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 105 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 106 KUWAIT ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 107 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 108 REST OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
Licence Rights
Section Purchase
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Products and Companies
Companies
AbbVie Inc.
BASF SE
Corbion NV
DSM
AstraZeneca
GlaxoSmithKline plc.
Strides Pharma Science Limited
Company Profile
Company Profile Title
Middle East and Africa omega-3 ingredients for pharmaceuticals market is projected to register a healthy CAGR of 8.4% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
Middle East and Africa Omega-3 Ingredients for Pharmaceuticals Market, By Source (Marine and Plant), Type (Docosahexaenoic Acid (DHA), Eicosapentaenoic Acid (EPA) and Alpha-Linolenic Acid (ALA)), Form (Liquid and Dry), Therapeutic Areas (Cardiovascular Diseases, Autoimmune Diseases, Bone & Joint Disorders, Neurological Disorders, Ophthalmic Disorders, Skin Health, Cancer and Others), Population Type (Adults and Children), Distribution Channel (Direct and Indirect), Country (South Africa, Saudi Arabia, U.A.E., Kuwait and Rest of Middle East and Africa) Industry Trends & Forecast to 2027
Some of the major factors contributing to the growth of Middle East and Africa omega-3 ingredients for pharmaceuticals market are:
Growing demand of functional and supplement food
Rising burden of lifestyle diseases leads the demand of Omega-3 based products
Market Players:
The key market players for Middle East and Africa omega-3 ingredients for pharmaceuticals market are listed below:
AbbVie Inc.
BASF SE
Corbion NV
DSM
AstraZeneca
GlaxoSmithKline plc.
Strides Pharma Science Limited
Scope
TABLE OF CONTENTS
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 SOURCE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.10 SECONDARY SOURCES
2.11 ASSUMPTIONS
3 EXECUTIVE SUMMARY
3.1 PATENT ANALYSIS
3.1.1 DBMR ANALYSIS
3.1.2 COUNTRY LEVEL INSIGHTS
3.1.3 COMPANY BASED ANALYSIS
3.2 PRICING ANALYSIS
4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: REGULATIONS
5 IMPACT OF COVID-19 PANDEMIC ON THE MIDDLE EAST AND AFRICA OMEGA 3 INGREDIENTS IN PHARMACEUTICALS MARKET
5.1 PRICE IMPACT
5.2 IMPACT ON DEMAND
5.3 IMPACT ON SUPPLY CHAIN
5.4 STRATEGIC DECISIONS FOR MANUFACTURERS
5.5 CONCLUSION
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 CONSUMER AWARENESS REGARDING THE HEALTH BENEFITS OF OMEGA-3
6.1.2 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD
6.1.3 INCREASING PREFERENCES TOWARDS CERTIFIED FOOD INGREDIENTS
6.1.4 RISING BURDEN OF LIFESTYLE DISEASES LEADS THE DEMAND OF OMEGA-3 BASED PRODUCTS
6.2 RESTRAINTS
6.2.1 NEGATIVE CONSUMER PERCEPTION ABOUT THE SMELL AND TASTE OF OMEGA-3 INGREDIENTS
6.2.2 HIGH COSTS OF PRODUCTS
6.3 OPPORTUNITIES
6.3.1 GROWING RESEARCH FOR THE DEVELOPMENT OF ALTERNATIVE SOURCES TO OBTAIN OMEGA-3
6.3.2 RISE IN CONSUMER DEMAND FOR PLANT-BASED OMEGA-3 PRODUCTS
6.3.3 DEVELOPING TECHNOLOGIES TO INCREASE THE CONCENTRATION OF OMEGA-3 INGREDIENTS IN MEDICINES
6.4 CHALLENGES
6.4.1 SIDE EFFECTS AND ALLERGIES RELATED TO FISH-BASED PRODUCTS
6.4.2 SUSTAINABILITY ISSUES WITH OMEGA-3 RAW MATERIAL
7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE
7.1 OVERVIEW
7.2 MARINE
7.3 PLANT
8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE
8.1 OVERVIEW
8.2 DOCOSAHEXAENOIC ACID (DHA)
8.3 EICOSAPENTAENOIC ACID (EPA)
8.4 ALPHA-LINOLENIC ACID (ALA)
9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM
9.1 OVERVIEW
9.2 LIQUID
9.3 DRY
10 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS
10.1 OVERVIEW
10.2 CARDIOVASCULAR DISEASES
10.2.1 HYPERLIPIDEMIA
10.2.2 STROKES
10.2.3 HYPERTENSION
10.2.4 OTHERS
10.3 CANCER
10.3.1 PROSTATE CANCER
10.3.2 BREAST CANCER
10.3.3 COLORECTAL CANCER
10.3.4 OTHERS
10.4 NEUROLOGICAL DISORDERS
10.4.1 ALZHEIMER'S DISEASE
10.4.2 COGNITIVE DISORDERS
10.4.3 BIPOLAR DISORDERS
10.4.4 SCHIZOPHRENIA
10.4.5 OTHERS
10.5 AUTOIMMUNE DISEASES
10.5.1 RHEUMATOID ARTHRITIS
10.5.2 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
10.5.3 TYPE 1 DIABETES
10.5.4 OTHERS
10.6 BONE & JOINT DISORDERS
10.6.1 OSTEOPOROSIS
10.6.2 ARTHRITIS
10.6.3 OTHERS
10.7 SKIN HEALTH
10.7.1 ACNE
10.7.2 WRINKLES
10.7.3 SKIN AGING
10.7.4 OTHERS
10.8 OPHTHALMIC DISORDERS
10.8.1 DRY EYE SYNDROME
10.8.2 AGE-RELATED MACULAR DEGENERATION
10.8.3 OTHERS
10.9 OTHERS
11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE
11.1 OVERVIEW
11.2 ADULT
11.2.1 FEMALE
11.2.2 MALE
11.3 CHILDREN
12 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL
12.1 OVERVIEW
12.2 DIRECT
12.3 INDIRECT
13 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY GEOGRAPHY
13.1 MIDDLE EAST & AFRICA
13.1.1 SOUTH AFRICA
13.1.2 UAE
13.1.3 SAUDI ARABIA
13.1.4 KUWAIT
13.1.5 REST OF MIDDLE EAST AND AFRICA
14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, COMPANY LANDSCAPE
14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
15 SWOT ANALYSIS
16 COMPANY PROFILE
16.1 CRODA INTERNATIONAL PLC
16.1.1 COMPANY SNAPSHOT
16.1.2 REVENUE ANALYSIS
16.1.3 COMPANY SHARE ANALYSIS
16.1.4 PRODUCT PORTFOLIO
16.1.5 RECENT DEVELOPMENT
16.2 CORBION
16.2.1 COMPANY SNAPSHOT
16.2.2 REVENUE ANALYSIS
16.2.3 COMPANY SHARE ANALYSIS
16.2.4 PRODUCT PORTFOLIO
16.2.5 RECENT DEVELOPMENTS
16.3 DSM
16.3.1 COMPANY SNAPSHOT
16.3.2 REVENUE ANALYSIS
16.3.3 COMPANY SHARE ANALYSIS
16.3.4 PRODUCT PORTFOLIO
16.3.5 RECENT DEVELOPMENTS
16.4 KD PHARMA GROUP
16.4.1 COMPANY SNAPSHOT
16.4.2 COMPANY SHARE ANALYSIS
16.4.3 PRODUCT PORTFOLIO
16.4.4 RECENT DEVELOPMENTS
16.5 STRIDES PHARMA SCIENCE LIMITED
16.5.1 COMPANY SNAPSHOT
16.5.2 REVENUE ANALYSIS
16.5.3 COMPANY SHARE ANALYSIS
16.5.4 PRODUCT PORTFOLIO
16.5.5 RECENT DEVELOPMENT
16.6 BASF SE
16.6.1 COMPANY SNAPSHOT
16.6.2 REVENUE ANALYSIS
16.6.3 PRODUCT PORTFOLIO
16.6.4 RECENT DEVELOPMENTS
16.7 PHARMA MARINE AS
16.7.1 COMPANY SNAPSHOT
16.7.2 PRODUCT PORTFOLIO
16.7.3 RECENT DEVELOPMENTS
16.8 ABBVIE INC.
16.8.1 COMPANY SNAPSHOT
16.8.2 REVENUE ANALYSIS
16.8.3 PRODUCT PORTFOLIO
16.8.4 RECENT DEVELOPMENT
16.9 AMARIN CORPORATION
16.9.1 COMPANY SNAPSHOT
16.9.2 REVENUE ANALYSIS
16.9.3 PRODUCT PORTFOLIO
16.9.4 RECENT DEVELOPMENTS
16.10 ANI PHARMACEUTICALS, INC.
16.10.1 COMPANY SNAPSHOT
16.10.2 REVENUE ANALYSIS
16.10.3 PRODUCT PORTFOLIO
16.10.4 RECENT DEVELOPMENT
16.11 ASTRAZENECA
16.11.1 COMPANY SNAPSHOT
16.11.2 REVENUE ANALYSIS
16.11.3 PRODUCT PORTFOLIO
16.11.4 RECENT DEVELOPMENT
16.12 AVESTIA PHARMA
16.12.1 COMPANY SNAPSHOT
16.12.2 PRODUCT PORTFOLIO
16.12.3 RECENT DEVELOPMENT
16.13 CAMBER PHARMACEUTICALS, INC.
16.13.1 COMPANY SNAPSHOT
16.13.2 PRODUCT PORTFOLIO
16.13.3 RECENT DEVELOPMENTS
16.14 EPAX (A SUBSIDIARY OF PELAGIA AS)
16.14.1 COMPANY SNAPSHOT
16.14.2 REVENUE ANALYSIS
16.14.3 PRODUCT PORTFOLIO
16.14.4 RECENT DEVELOPMENTS
16.15 FRESENIUS KABI INDIA PVT. LTD. (A SUBSIDIARY OF FRESENIUS KABI AG)
16.15.1 COMPANY SNAPSHOT
16.15.2 REVENUE ANALYSIS
16.15.3 PRODUCT PORTFOLIO
16.15.4 RECENT DEVELOPMENT
16.16 GLAXOSMITHKLINE PLC
16.16.1 COMPANY SNAPSHOT
16.16.2 REVENUE ANALYSIS
16.16.3 PRODUCT PORTFOLIO
16.16.4 RECENT DEVELOPMENT
16.17 KINOMEGA BIOPHARM INC
16.17.1 COMPANY SNAPSHOT
16.17.2 PRODUCT PORTFOLIO
16.17.3 RECENT DEVELOPMENTS
16.18 NOVASEP
16.18.1 COMPANY SNAPSHOT
16.18.2 REVENUE ANALYSIS
16.18.3 PRODUCT PORTFOLIO
16.18.4 RECENT DEVELOPMENT
16.19 SOLUTEX
16.19.1 COMPANY SNAPSHOT
16.19.2 PRODUCT PORTFOLIO
16.19.3 RECENT DEVELOPMENT
17 QUESTIONNAIRE
18 RELATED REPORTS
List Of Figure
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SEGMENTATION
FIGURE 10 GROWING DEMAND OF FUNCTIONAL AND SUPPLEMENT FOOD IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN THE FORECAST PERIOD OF 2020 TO 2027
FIGURE 11 MARINE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET IN 2020 & 2027
FIGURE 12 PATENT REGISTERED FOR OMEGA-3, BY COUNTRY
FIGURE 13 PATENT REGISTERED BY YEAR (2000-2020)
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET
FIGURE 15 PREVALENCE OF LIFESTYLE CHRONIC DISEASES (IN MILLIONS)
FIGURE 16 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019
FIGURE 17 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, 2019-2027 (USD THOUSANDS)
FIGURE 18 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, CAGR (2020-2027)
FIGURE 19 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019
FIGURE 21 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, 2019-2027 (USD THOUSANDS)
FIGURE 22 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, CAGR (2020-2027)
FIGURE 23 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019
FIGURE 25 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, 2019-2027 (USD THOUSANDS)
FIGURE 26 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, CAGR (2020-2027)
FIGURE 27 MIDDLE EAST AND AFRICA TREATMENT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY FORM, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, 2019
FIGURE 29 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC ARES, 2019-2027 (USD THOUSANDS)
FIGURE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, CAGR (2020-2027)
FIGURE 31 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY THERAPEUTIC AREAS, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019
FIGURE 33 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, 2019-2027 (USD THOUSANDS)
FIGURE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, CAGR (2020-2027)
FIGURE 35 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019
FIGURE 37 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, 2019-2027 (USD THOUSANDS)
FIGURE 38 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)
FIGURE 39 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: SNAPSHOT (2019)
FIGURE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2019)
FIGURE 42 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY(2020& 2027)
FIGURE 43 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY COUNTRY (2019& 2027)
FIGURE 44 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: BY SOURCE (2020-2027)
FIGURE 45 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET: COMPANY SHARE 2019 (%)
List Of Table
LIST OF TABLES
TABLE 1 THE PRICE RANGE OF OMEGA-3 INGREDIENTS
TABLE 2 COST COMPARISION OF MARINE SOURCES OF OMEGA-3 INGREDIENTS
TABLE 3 COST OF PRODUCTS
TABLE 4 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 5 MIDDLE EAST AND AFRICA MARINE IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 6 MIDDLE EAST AND AFRICA PLANT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 7 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 8 MIDDLE EAST AND AFRICA DOCOSAHEXAENOIC ACID (DHA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 9 MIDDLE EAST AND AFRICA EICOSAPENTAENOIC ACID (EPA) IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 10 MIDDLE EAST AND AFRICA ALPHA-LINOLENIC ACID (ALA)IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 11 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM , 2017-2026 (USD THOUSANDS)
TABLE 12 MIDDLE EAST AND AFRICA LIQUID IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 13 MIDDLE EAST AND AFRICA DRY IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 14 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 15 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 16 MIDDLE EAST AND AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 17 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 18 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 19 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 20 MIDDLE EAST AND AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 21 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 22 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 23 MIDDLE EAST AND AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 24 MIDDLE EAST AND AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 25 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 26 MIDDLE EAST AND AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 27 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 28 MIDDLE EAST AND AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 29 MIDDLE EAST AND AFRICA OTHERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 30 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 31 GLOBA ADULT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 32 MIDDLE EAST AND AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 33 GLOBA CHILDREN IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2017-2026 (USD THOUSANDS)
TABLE 34 MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 35 MIDDLE EAST AND AFRICA DIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 36 MIDDLE EAST AND AFRICA INDIRECT IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY REGION, 2018-2027 (USD THOUSANDS)
TABLE 37 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY COUNTRY, 2018-2027 (USD THOUSANDS)
TABLE 38 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 39 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 40 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 41 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 42 MIDDLE EAST & AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 43 MIDDLE EAST & AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 44 MIDDLE EAST & AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 45 MIDDLE EAST & AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 46 MIDDLE EAST & AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 47 MIDDLE EAST & AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 48 MIDDLE EAST & AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 49 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 50 MIDDLE EAST & AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 51 MIDDLE EAST & AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 52 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 53 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 54 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 55 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 56 SOUTH AFRICA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 57 SOUTH AFRICA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 58 SOUTH AFRICA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 59 SOUTH AFRICA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 60 SOUTH AFRICA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 61 SOUTH AFRICA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 62 SOUTH AFRICA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 63 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 64 SOUTH AFRICA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 65 SOUTH AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 66 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 67 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 68 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 69 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 70 UAE OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 71 UAE NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 72 UAE CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 73 UAE AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 74 UAE CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 75 UAE BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 76 UAE SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 77 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 78 UAE ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 79 UAE OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 80 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 81 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 82 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 83 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 84 SAUDI ARABIA OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 85 SAUDI ARABIA NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 86 SAUDI ARABIA CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 87 SAUDI ARABIA AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 88 SAUDI ARABIA CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 89 SAUDI ARABIA BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 90 SAUDI ARABIA SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 91 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 92 SAUDI ARABIA ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 93 SAUDI ARABIA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 94 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
TABLE 95 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY TYPE, 2018-2027 (USD THOUSANDS)
TABLE 96 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY FORM, 2018-2027 (USD THOUSANDS)
TABLE 97 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 98 KUWAIT OPHTHALMIC DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 99 KUWAIT NEUROLOGICAL DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 100 KUWAIT CARDIOVASCULAR DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 101 KUWAIT AUTOIMMUNE DISEASES IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 102 KUWAIT CANCER IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 103 KUWAIT BONE & JOINT DISORDERS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 104 KUWAIT SKIN HEALTH IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY THERAPEUTIC AREAS, 2018-2027 (USD THOUSANDS)
TABLE 105 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 106 KUWAIT ADULTS IN OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY POPULATION TYPE, 2018-2027 (USD THOUSANDS)
TABLE 107 KUWAIT OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD THOUSANDS)
TABLE 108 REST OF MIDDLE EAST AND AFRICA OMEGA-3 INGREDIENTS FOR PHARMACEUTICALS MARKET, BY SOURCE, 2018-2027 (USD THOUSANDS)
INQUIRE FOR COVID-19 IMPACT ANALYSIS
Companies
AbbVie Inc.
BASF SE
Corbion NV
DSM
AstraZeneca
GlaxoSmithKline plc.
Strides Pharma Science Limited
: +91 9015378249
Related Reports
Page 157 | 
June 2021
Page 130 | December 2020
Page 130 | December 2020
Page 131 | November 2020
Page 95 | November 2020